---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-152323"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2024-06-03T23:59:59+00:00"
generated_at: "2026-06-01T06:43:21.614825+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Edwards Lifesciences sells Critical Care unit to BD for $4.2B cash, ends spin-off

## Summary
- All-cash sale of Critical Care product group to BD (NYSE: BDX) valued at $4.2 billion.
- Edwards will no longer pursue the previously announced spin-off of Critical Care.
- Transaction expected to close by end of 2024; impact to 2024 adjusted EPS immaterial.
- Critical Care will remain in Irvine, CA, led by current corporate VP Katie Szyman.
- After-tax cash proceeds to fund strategic structural heart innovation investments.

## SEC filing metadata
- accession: 0001193125-24-152323
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2024-06-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000119312524152323/0001193125-24-152323-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000119312524152323/d836710d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-152323
- JSON: https://secwatch.observer/filing/0001193125-24-152323.json
- Plain text: https://secwatch.observer/filing/0001193125-24-152323.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.